18F-FDG simultaneous PET/MR findings of a malignant transformation and metastases of abdominal wall endometriosis

IMAGE OF THE MONTH 18F-FDG simultaneous PET/MR findings of a malignant transformation and metastases of abdominal wall endometriosis Haiyan Wang1 & Qiaoyi Xue2 & Yi Shou 1 & Xing Chen 1 & Zhiwen You1 & Jianmin Yuan2 & Jinli Gao 3 & Jun Zhao 1 Received: 11 February 2020 / Accepted: 4 March 2020 # The Author(s) 2020 Abdominal wall endometriosis (AWE) arising from a surgical scar of cesarean delivery or other abdominopelvic operation, is a rare event with an incidence of 0.03 to 2% [ 1, 2]. Malignant transformation of AWE is an extremely rare disease, with few cases reported in the literature [ 3–5], and the atypical mecha- nism for progression to carcinoma remains unknown. The most frequent histological type of malignancy developing from extraovarian endometriosis is clear cell adenocarcinoma, follow- ed by endometrioid adenocarcinoma [2, 6, 7]. Surgery and ad- juvant chemotherapy are the primary treatment options. High mortality rate was found up to 50 months following diagnosis, with median survival time of 42 months after the diagnosis. Routine CT and MRI imaging are not sensitive in detecting malignancy and there is no specific clinical marker for malignant transformation. Whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/ CT) has been demonstrated to be a sensitive and well- established imaging modality for detection, staging/re-staging, and evaluation of therapy response of solid tumors. Simultaneous 18F-FDG positron emission tomography/ magnetic resonance (PET/MR) has the potential to play an im- portant role in identifying the malignancy and the evaluation of clinical staging because MRI has higher soft tissue contrast and no ionizing radiation exposure compared to CT. We herein report a case of a 43-year-old woman with clear cell adenocarcinoma arising from malignant transformation of AWE 19 years after cesarean section. She was initially hospi- talized for abdominal wall mass 3 months ago. The 10 × 5 cm of mass was palpated in the right lower abdomen. The mass was firm, tenacious, indolent to palpation, and had poor mo- bility. Abdominal needle biopsy was performed, and the his- topathological results confirmed adenocarcinoma. Cancer an- tigen (CA) 125 level before the surgery was 26.20 IU/ml. The patient was then sent for whole-body Fluorine-18 FDG positron emission tomography magnetic resonance (18F-FDG PET/MR) assessment for preoperative staging. A hybrid 3.0 T PET/MR scanner (uPMR 790, UIH, Shanghai, China) was used. Default clinical MRI sequences including T1w and T2w were scanned. 18F-FDG PET/MR imaging revealed a 9.4 × 4.6 × 4.8 cm solid, heterogenic mass in the abdominal wall on its exterior part, partially involving the right rectus abdominal muscle, with significantly increased FDG uptake (SUVmax = 9.61). Several enlarged retroperitoneal lymph nodes and left inguinal lymph nodes with high FDG uptake were also found in PET/MR-fused images (SUVmax = 4.25). There was no abnormal 18F-FDG uptake in the uterus and bilateral ovaries. An extensive resection with bilateral appendectomy of uterus, pelvic lymph node cleaning, and reconstruction of the abdominal wall was performed. During the operation, a mass of 10 × 5 × 5 cm was found in the lower right rectus abdominis and between the peritoneum. The mass was firmly attached to the rectus abdominis, and it was difficult to sepa- rate it from healthy tissue. Multiple enlargement and fused lymph nodes were found in the bilateral iliac blood vessels and around the retroperitoneum. No obvious mass was found in the uterus and bilateral ovaries, and no effusion/infiltration was found in the abdominal and pelvic cavity. Histopathological diagnosis was a stage IIIc clear cell ade- nocarcinoma originated in ectopic endometrial tissue, and 51 lymph nodes out of 69 ones was positive. Chemotherapy with taxol and carboplatin was then initiated. Haiyan Wang and Qiaoyi Xue contributed equally to this work. This article is part of the Topical Collection on Image of the Month * Jinli Gao [email protected] * Jun Zhao [email protected] 1 Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China 2 Central Research Institute, UIH Group, Shanghai, China 3 Department of Pathology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China https://doi.org/10.1007/s00259-020-04761-7 / Published online: 25 April 2020 European Journal of Nuclear Medicine and Molecular Imaging (2020) 47:3190–3191 Acknowledgments We thank Dr. Lingzhi Hu, Ph.D.(Director of PET/MR, United Imaging Healthcare) who provided imaging technological support. Funding information T h i ss t u d yw a sf u n d e db yt h eK e yS p e c i a l t y Construction Project of Pudong Health and Family Planning Commission of Shanghai, PWZzk2017-24. Compliance with ethical standards Conflict of interest The authors declare that they have no conflict of interest. Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institu- tional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent Informed consent was obtained from the patient for the anonymous use of her clinical, imaging, and histologic data for publication. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adap- tation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, pro- vide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. References 1. Bektas H, Bilsel Y , Sari YS, et al. Abdominal wall endometrioma: a 10-year experience and brief review of the literature. J Surg Res. 2010;164:e77–81. 2. Mihailovici A, Rottenstreich M, Kovel S, et al. Endometriosis-associated malignant transformation in abdominal surgical scar: a PRISMA- compliant systematic review. Medicine. 2017;96(49):e9136. 3. Djakovic I, Vukovic A, Bolanca I, et al. Abdominal wall endometri- osis eleven years after cesarean section: case report. Acta Clin Croat. 2017;56:162–5. 4. Bats AS, Zafrani Y , Pautier P , et al. Malignant transformation of abdominal wall endometriosis to clear cell carcinoma: case report and review of the literature. Fertil Steril. 2008;90:1197.e13–6. 5. Jiang M, Chen P , Sun L, et al. 18F-FDG PET/CT finding of a recur- rent adenocarcinoma arising from malignant transformation of ab- dominal wall endometriosis. Clin Nucl Med. 2015;40:184–5. 6. Sosa-Duran EF, Aboharp-Hasan Z, Mendoza-Morales RC, et al. Clear cell adenocarcinoma arising from abdominal wall endometri- osis. Cirugia y Cirujanos. 2016;84(3):245–9. 7. Marchand E, Hequet D, Thoury A, et al. Malignant transformation of superficial peritoneal endometriosis lesion. BMJ Case Rep. 2013. https://doi.org/10.1136/bcr-2012-007730. Publisher’sn o t eSpringer Nature remains neutral with regard to jurisdic- tional claims in published maps and institutional affiliations. 3191Eur J Nucl Med Mol Imaging (2020) 47:3190–3191